Christine Crews thought she had a bladder infection she just couldn’t shake. Turns out, the Memphis, Tenn., resident had been living with bladder cancer for 15 years.
A surgeon recommended invasive surgery, but Crews wasn’t comfortable with that recommendation; she wanted other options. When a urologist friend recommended she call City of Hope, she did.
“They actually listened to what I wanted from the surgery,” Crews said. “They were able to give me options that other hospitals were not able to give me.”
In the video above, Crews shares her story to help other people with bladder cancer understand just how special City of Hope is, and what their options really are.
Read the Breakthroughs post “8 questions and answers about bladder cancer.”
Learn more about City of Hope’s bladder cancer program.
“Susan survived breast cancer 20 years ago.” So begins a video of a former City of Hope patient sharing the story of her lung cancer diagnosis and her subsequent treatment at City of Hope.
In her narrative, the former patient expresses shock at her diagnosis, saying she was “totally floored.” After all, she’d never smoked, and the common perception of lung cancer has been that it’s a disease only of smokers. That perception is slowly changing.
As explained by Karen Reckamp, M.D., M.S., co-director of City of Hope’s Lung Cancer and Thoracic Oncology Program: “The most common cause of lung cancer is tobacco smoke, and the risk increases with the quantity and duration of smoking. Yet nearly 15 percent of those who develop lung cancer have never smoked, so there are other factors clearly involved such as the environment and genetics. Although these causes are not well-outlined, research is ongoing to improve our understanding of nonsmoking-related lung cancers.” » Continue Reading
Women undergoing radiation treatment for breast cancer should try yoga. That’s the take-home message of a new study linking yoga to a greater sense of well-being and better regulation of stress hormones among female breast cancer patients.
The study, published online March 3 in the Journal of Clinical Oncology, was conducted by researchers at M.D. Anderson Cancer Center and adds to increasing evidence that exercise benefits cancer patients.
“This study supports that the more you do, the better off you are,” said City of Hope’s Joanne Mortimer, M.D., providing expert commentary on the study to HealthDay. Mortimer is director of Women’s Cancers Programs.
To measure the impact of yoga, researchers assigned women undergoing radiation therapy to one of three groups. One group practiced yoga for up to three times a week, one group did stretching exercises for up to three times a week and one group did neither. Participants in each group shared with researchers their feelings of fatigue and how that impacted their quality of life, as well as their levels of depression and sleep disturbances. They also gave saliva samples so researchers could measure their levels of cortisol, considered an indicator of stress. » Continue Reading
Every field has its stars, and nursing research is certainly no exception. One of those stars – City of Hope’s Betty Ferrell, Ph.D., R.N., – will soon be inducted into the International Nurse Researcher Hall of Fame by the Honor Society of Nursing, Sigma Theta Tau International (STTI).
A pioneer in the field of palliative care nursing, Ferrell is City of Hope’s director of Nursing Research and Education. She will join 24 other nurses being inducted this year. The award recognizes nurse researchers who have achieved national or international recognition and whose work has improved the nursing profession and the patients it serves. The honorees’ research projects will be shared through the Virginia Henderson International Nursing e-Repository, allowing nurses around the globe to benefit from their discoveries.
“The combined accomplishments of these 25 honorees are nothing short of world-changing,” said Hester C. Klopper, Ph.D., M.B.A., R.N., R.M., STTI president. “In keeping with the STTI mission to celebrate nursing excellence in scholarship, leadership and service, I congratulate the 2014 Nurse Researcher Hall of Fame honorees.” » Continue Reading
Bladder cancer incidence rates have not increased over the past few years — which is a good thing. But unlike cancers of the colon, prostate and lung, they haven’t declined either.
With more than 74,690 new cases of bladder cancer diagnosed in the United States each year and approximately 15, 580 deaths from the disease, it’s imperative to find the underlying causes of bladder cancer and why the incidence rate remains stubbornly unchanged.
What is the current trend for bladder cancer incidence rates?
When reviewing the most recent American Cancer Society statistics, it appears as though bladder cancer incidences have flat-lined to some extent. This is disappointing because there are several other cancers indicated in the same annual report that appear to be on the decline. For instance, the incidence rates on prostate cancer in broad terms seem to be falling.
Furthermore, incidence rates of lung cancer and colorectal cancer also appear to be falling. This may potentially reflect little change in terms of bladder cancer screening; whereas for colorectal cancer and prostate cancer, there’s been a great extent of literature on cancer screening. We just don’t have the same in the context of bladder cancer.
When Ralph Richardson discovered that his prostate-specific antigen (PSA) reading was a 6, he told his primary care physician that he wanted to go to City of Hope. “I felt I was better off in a City of Hope environment, where it’s a cancer treatment specialty hospital. This is what they do,” Richardson said.
At City of Hope, Richardson met with Jonathan Yamzon, M.D., clinical professor in the Prostate Cancer Program. “After Ralph’s biopsy revealed prostate cancer, we discussed the parameters used to stratify his risk of disease progression, and he fell into the ‘low-risk’ category. With that, we discussed his options, including treatment with robotic-assisted surgery or radiation therapy, versus active surveillance. Since his cancer risk was low, I recommended active surveillance as the most appropriate treatment,” Yamzon said.
A new test that allows researchers to quickly identify drugs and chemicals that could disrupt the balance of hormones in the body – potentially affecting development and progression of cancer, including breast cancer – has raised worries about the common antidepressant Paxil.
In a trial screening of 446 common drugs, paroxetine – commercially known as Paxil – was found to have a weak estrogen-boosting effect, while other drugs were found to have slight estrogen-inhibiting effects. The implications for such an assay – developed at City of Hope – are significant, but it was the Paxil finding that grabbed national media attention. With 12 percent of Americans age 12 and older taking some form of antidepressant, the study and ensuing coverage raised concern among many women that Paxil might promote the growth of breast tumors.
A City of Hope women’s health expert says the new research has a larger message. The message isn’t that women should stop important medications – but rather that scientists and physicians should focus on increased opportunities for breast cancer research.
“They’re very important drugs from a quality-of-life standpoint,” said Joanne Mortimer, M.D., director of Women’s Cancers Programs at City of Hope. “No drug has a single effect on the body. Every drug has many different effects. It’s really important to know that, and to be able to measure this in the laboratory, but ultimately we don’t know at this point what impact they have on breast cancer. What comes out of the lab isn’t the same as what happens when you put this in the human body.” » Continue Reading
No matter how impressive a research study’s conclusion may be – or how seemingly unsurprising – experts are needed to put the findings into context. Perhaps a study’s methodology wasn’t as strong as it could have been. Perhaps the conclusions confirmed that other researchers are on the right track. Perhaps the study missed the mark completely.
City of Hope’s physicians recently weighed in on an array of recent published studies, offering their expertise, insight and perspective via a special commentary feature in Clinical Oncology News.
From Journal of the National Cancer Institute came this recent study: “More Exercise Is Better During Breast Cancer Chemotherapy.”
Commented Joanne Mortimer, M.D., director of the Women’s Cancers Program and professor and vice chair of the Department of Medical Oncology & Therapeutics Research at City of Hope:
The researchers “demonstrated that as little as 25 to 30 minutes of vigorous aerobic exercise three times a week can improve self-reported physical functioning in women undergoing adjuvant chemotherapy. Twice that amount of aerobic exercise resulted in a significant reduction in bodily pain and fatigue. … The relationship between physical activity, obesity and breast cancer continues to intrigue us and provide important biological insights.” » Continue Reading
Research studies known as clinical trials have led to countless advances in the diagnosis, treatment and prevention of cancer. These studies test the effectiveness of new medical approaches that can lead to fewer treatment-related side effects and, in some cases, improved outcomes for patients with certain cancers.
But many patients know little about clinical trials, much less what’s involved to participate. Here, Leslie Popplewell, associate professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, explains how clinical trials work and how patients and their families can make informed decisions about participating in trials.
What are clinical trials, and why are they important?
Clinical trials are a way of delivering a promising new drug or combination of drugs to patients. Trials typically have a strict set of guidelines on which patients can be treated (“are eligible”), and they’re carefully controlled so that the results can be recorded and the outcomes reported in a scientific way.
Usually clinical trials are designed to test new drugs, or drugs that have been in use for a while, but are now used in a different setting or patient population than previously. A clinical trial may also offer a new drug combination that hasn’t been used before. » Continue Reading
Many cancer incidence rates decline over time, but kidney cancer is one of the few cancers with incidence rates that continue to rise year after year.
Currently, nearly 64,000 new cases of kidney cancer are diagnosed in the United States each year, and approximately 13,860 people die from it, according to the American Cancer Society. Men are much more likely than women to be diagnosed with the disease and to die from it.
But unlike other cancers, there is no formalized way to detect kidney cancer, which is why it’s important to know the disease’s risk factors and symptoms. Here Sumanta Kumar Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, explores both the factors behind the rise in kidney cancer and the disease’s current treatments.
While most cancer incident rates continue to drop each year, kidney cancer is one of the few that continue to increase. Why is this?
Unlike breast cancer or colon cancer, kidney cancer is a disease for which we have no good screening modalities. At the moment, there’s no formalized way to actually detect kidney cancer before the onset of the disease. But as time has gone on, our imaging modalities have gotten better and better — what I’m referring to here are CT scans and MRIs — and as that happened, we’ve found more and more incidental diagnosis of kidney cancer. » Continue Reading